Pharmacokinetics of low doses of colchicine in the leukocytes of Japanese healthy individuals
- Author:
Akiko MUTOH
1
;
Hitoshi UEHARA
;
Asano MAEDA
;
Akihiro TOKUSHIGE
;
Yasushi HIGASHIUESATO
;
Mika MAEDA
;
Yuji KUMAGAI
;
Shinichiro UEDA
Author Information
- Publication Type:Original Article
- From:Translational and Clinical Pharmacology 2023;31(4):217-225
- CountryRepublic of Korea
- Language:English
- Abstract: The venerable drug colchicine has garnered significant recent attention due to its endorsement by the United States Food and Drug Administration as an anti-inflammatory medication for cardiovascular diseases. However, the administration of this drug at its minimal available dose of 0.5 mg has been associated with certain adverse reactions.Once colchicine is administered, the drug disappears from blood in a short time and distributes in the leukocytes for a certain period of time that elicits anti-inflammatory effect.Consequently, an in-depth comprehension of the pharmacokinetics of lower dosages within leukocytes assumes important for its broader application in routine clinical contexts. In this study, we present a comprehensive analysis of the pharmacological disposition of colchicine in the plasma, polymorphonuclear leukocytes, and mononuclear leukocytes among healthy Japanese male subjects, following both single and multiple oral administrations of 0.5 mg and 0.25 mg doses of colchicine. Our investigation reveals that colchicine persists within leukocyte populations even when administered at reduced dosages. The findings herein hold promise for mitigating the adverse effects associated with its use in the treatment of inflammatory cardiovascular disorders.
